## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.9% in upper entry zone (3.0-6.0%), top 8% cross-sectional ranking. Short-term MRS_5 (2.7%) confirms momentum alignment. Strong momentum (+1.1% 5-day acceleration). Outperforming sector by 4.2%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($11.12)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Lost Money on Viatris Inc. (VTRS)? Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky**
- Source: WJBF | 20251217T000854 | Bearish | Relevance: 100%
- Levi & Korsinsky LLP has filed a class action securities lawsuit against Viatris Inc. (NASDAQ: VTRS) for alleged securities fraud between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of an FDA warning letter, which led to a significant stock price decline after disappointing Q4 2024 financial results and 2025 guidance. Shareholders who suffered losses are encouraged to contact the firm to learn about their rights to recovery before June 3, 2025.

**2. Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: PR Newswire | 20251217T120828 | Neutral | Relevance: 100%
- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026. The presentation and fireside chat will begin at 9 a.m. PT / 12 p.m. ET and will be available via live webcast and an archived version on the company's investor relations website.

**3. Is Viatris Stock Outperforming the Dow?**
- Source: Barchart.com | 20251215T153554 | Neutral | Relevance: 100%
- Viatris Inc. (VTRS) is a large-cap healthcare company valued at $13.4 billion, trading 7.7% below its 52-week high. While it has outperformed the Dow Jones Industrial Average with a 22.9% rise in the past three months, VTRS has lagged in longer terms, declining 6.6% over the past 52 weeks and 5.3% YTD. Despite recent Q3 earnings showing a revenue increase but EPS decline, analysts maintain a "Moderate Buy" rating with a 6.6% premium target.

**4. Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back**
- Source: The Globe and Mail | 20251216T160825 | Bullish | Relevance: 100%
- Viatris Inc. has been recognized as one of the 2025 Best Workplaces™ in Ontario and for Giving Back in Canada. These awards highlight Viatris's dedication to creating a positive work environment where colleagues feel valued and engaged, as well as the company's commitment to meaningful community involvement.

**5. Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: StreetInsider | 20251217T120252 | Neutral | Relevance: 99%
- Viatris Inc. announced it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026. The presentation and fireside chat will begin at 9 a.m. PT / 12 p.m. ET, with a live webcast available on the company's investor relations website. An archived version will also be accessible for a limited time after the event.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $15 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +1.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 4.8x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.5B |
| Beta | 0.83 |
| 52W Range | $6.85 - $12.74 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 4.8 |
| Current P/E | 5.1 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 4.8% to 5.9% (+1.1% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 92nd percentile. MRS_5 at 2.7% confirms short-term momentum alignment. Outperforming sector by 4.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.91% (CS: 92) | Strong |
| RSI_14 | 69.3 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.066x | Above |
| vs SMA50 | 1.104x | Above |
| vs SMA200 | 1.230x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $11.70
- **Stop Loss:** $11.12 (5.0% risk)
- **Target:** $12.57 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1862
- **Position Value:** $21,785.40
- **Portfolio %:** 21.79%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_10*